Our studies focus on bacteria of the human microbiome including Campylobacter and Helicobacter species that live in the mucus layer overlying the mucosal epithelium of mammals, including humans. Specifically, we explore the biology of colonization and the nature of the interactions that lead to (or protect from) disease. For the normal microbiome, we study how early life perturbations affect host developmental phenotypes. Our on-going work focuses on the metabolic syndrome, and specifically on obesity and type 2 diabetes, as well as inflammatory disorders such as type 1 diabetes, asthma, psoriasis, and skin infections.
Muriel G. and George W. Singer Professor of Translational Medicine, Department of Medicine
Professor, Department of Microbiology
Director Human Microbiome Program
MD from New York University
Nature communications. 2017 Sep 11; 8(1):518-518
PLoS one. 2017 Aug 30; 12(8):e0184046-e0184046e0184046
Microbiome. 2017 Aug 25; 5(1):108-108
Nature reviews. Immunology. 2017 Jul 27; 17(8):461-463
Exposure to a single early life antibiotic pulse accelerated type 1 diabetes development in NOD mice [Meeting Abstract]
Endocrine reviews. 2017 June; Conference:(99th):
International journal of systematic & evolutionary microbiology. 2017 May 30; 67(5):1247-1254
The Contribution of Microbiome Alterations to Atherosclerotic Plaque Regression in Mice [Meeting Abstract]
Arteriosclerosis, thrombosis, & vascular biology. 2017 MAY; 37:?-?
Microbiome. 2017 Apr 24; 5(1):45-45